Vol , Issue Date of Publication: April 01, 2005
DOI: https://doi.org/10.20529/IJME.2005.032

Views
, PDF Downloads:

Drug deals

Bashir Mamdani
Abstract:
While justifying high prices by the high risk of failure of new drugs, the industry consistently reports higher profits than any other industry, 17% vs 3.1% for all the other industries on the Fortune 500 list – hardly a sign of high risk. The high profits reflect the exorbitant prices, particularly in the US, where, unlike most countries, there is no governmental mechanism to regulate drug prices.


Copyright and license
©Indian Journal of Medical Ethics 2016: Open Access and Distributed under the Creative Commons license ( CC BY-NC-ND 4.0),
which permits only non-commercial and non-modified sharing in any medium, provided the original author(s) and source are credited.

Full Text

HTML | PDF
Help IJME keep its content free. You can support us from as little as Rs. 500 Make a Donation